MaghrebDataLibMedV1, Main, Exploration, bibRecord, 000220

Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.

Identifieur interne : 000220 ( Main/Exploration ); précédent : 000219; suivant : 000221

Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.

Auteurs : Germain Honvo [Belgique] ; Jean-Yves Reginster [Belgique] ; Véronique Rabenda [Belgique] ; Anton Geerinck [Belgique] ; Ouafa Mkinsi [Maroc] ; Alexia Charles [Belgique] ; Rene Rizzoli [Belgique, Suisse] ; Cyrus Cooper [Belgique, Royaume-Uni] ; Bernard Avouac [Belgique] ; Olivier Bruyère [Belgique]

Source :

Drugs & aging [ 1179-1969 ] ; 2019.

RBID : pubmed:31073924

Descripteurs français

KwdFr :
- Anthraquinones (administration et posologie), Anthraquinones (effets indésirables), Anthraquinones (usage thérapeutique), Anti-inflammatoires non stéroïdiens (administration et posologie), Anti-inflammatoires non stéroïdiens (effets indésirables), Arthrose (traitement médicamenteux), Association médicamenteuse (MeSH), Effets secondaires indésirables des médicaments (épidémiologie), Effets secondaires indésirables des médicaments (étiologie), Essais contrôlés randomisés comme sujet (MeSH), Extraits de plantes (administration et posologie), Extraits de plantes (effets indésirables), Extraits de plantes (usage thérapeutique), Humains (MeSH), Phytostérols (administration et posologie), Phytostérols (effets indésirables), Phytostérols (usage thérapeutique), Préparations à action retardée (MeSH), Résultat thérapeutique (MeSH), Vitamine E (administration et posologie), Vitamine E (effets indésirables), Vitamine E (usage thérapeutique).
MESH :
- administration et posologie : Anthraquinones, Anti-inflammatoires non stéroïdiens, Extraits de plantes, Phytostérols, Vitamine E.
- effets indésirables : Anthraquinones, Anti-inflammatoires non stéroïdiens, Extraits de plantes, Phytostérols, Vitamine E.
- traitement médicamenteux : Arthrose.
- usage thérapeutique : Anthraquinones, Extraits de plantes, Phytostérols, Vitamine E.
- épidémiologie : Effets secondaires indésirables des médicaments.
- étiologie : Effets secondaires indésirables des médicaments.
- Association médicamenteuse, Essais contrôlés randomisés comme sujet, Humains, Préparations à action retardée, Résultat thérapeutique.

English descriptors

KwdEn :
- Anthraquinones (administration & dosage), Anthraquinones (adverse effects), Anthraquinones (therapeutic use), Anti-Inflammatory Agents, Non-Steroidal (administration & dosage), Anti-Inflammatory Agents, Non-Steroidal (adverse effects), Delayed-Action Preparations (MeSH), Drug Combinations (MeSH), Drug-Related Side Effects and Adverse Reactions (epidemiology), Drug-Related Side Effects and Adverse Reactions (etiology), Humans (MeSH), Osteoarthritis (drug therapy), Phytosterols (administration & dosage), Phytosterols (adverse effects), Phytosterols (therapeutic use), Plant Extracts (administration & dosage), Plant Extracts (adverse effects), Plant Extracts (therapeutic use), Randomized Controlled Trials as Topic (MeSH), Treatment Outcome (MeSH), Vitamin E (administration & dosage), Vitamin E (adverse effects), Vitamin E (therapeutic use).
MESH :
- chemical , administration & dosage : Anthraquinones, Anti-Inflammatory Agents, Non-Steroidal, Phytosterols, Plant Extracts, Vitamin E.
- chemical , adverse effects : Anthraquinones, Anti-Inflammatory Agents, Non-Steroidal, Phytosterols, Plant Extracts, Vitamin E.
- chemical , therapeutic use : Anthraquinones, Phytosterols, Plant Extracts, Vitamin E.
- chemical : Delayed-Action Preparations, Drug Combinations.
- drug therapy : Osteoarthritis.
- epidemiology : Drug-Related Side Effects and Adverse Reactions.
- etiology : Drug-Related Side Effects and Adverse Reactions.
- Humans, Randomized Controlled Trials as Topic, Treatment Outcome.

Abstract

BACKGROUND

Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are an important drug class in the treatment armamentarium for osteoarthritis (OA).

OBJECTIVE

We aimed to re-assess the safety of various SYSADOAs in a comprehensive meta-analysis of randomized placebo-controlled trials, using, as much as possible, data from full safety reports.

METHODS

We performed a systematic review and random-effects meta-analyses of randomized, double-blind, placebo-controlled trials that assessed adverse events (AEs) with various SYSADOAs in patients with OA. The databases MEDLINE, Cochrane Central Register of Controlled Trials (Ovid CENTRAL) and Scopus were searched. The primary outcomes were overall severe and serious AEs, as well as AEs involving the following Medical Dictionary for Regulatory Activities (MedDRA) system organ classes (SOCs): gastrointestinal, cardiac, vascular, nervous system, skin and subcutaneous tissue, musculoskeletal and connective tissue, renal and urinary system.

RESULTS

Database searches initially identified 3815 records. After exclusions according to the selection criteria, 25 studies on various SYSADOAs were included in the qualitative synthesis, and 13 studies with adequate data were included in the meta-analyses. Next, from the studies previously excluded according to the protocol, 37 with mainly oral nonsteroidal anti-inflammatory drugs (NSAIDs) permitted as concomitant medication were included in a parallel qualitative synthesis, from which 18 studies on various SYSADOAs were included in parallel meta-analyses. This post hoc parallel inclusion was conducted because of the high number of studies allowing concomitant anti-OA medications. Indeed, primarily excluding studies with concomitant anti-OA medications was crucial for a meta-analysis on safety. The decision for parallel inclusion was made for the purpose of comparative analyses. Glucosamine sulfate (GS), chondroitin sulfate (CS) and avocado soybean unsaponifiables (ASU; Piascledine

CONCLUSIONS

GS and CS can be considered safe treatments for patients with OA. All eligible studies on ASU included in our analysis used the proprietary product Piascledine

DOI: 10.1007/s40266-019-00662-z
PubMed: 31073924
PubMed Central: PMC6509099

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000251
to stream Main, to step Curation: 000251

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.</title>
<author><name sortKey="Honvo, Germain" sort="Honvo, Germain" uniqKey="Honvo G" first="Germain" last="Honvo">Germain Honvo</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. germain.honvo@uliege.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium. germain.honvo@uliege.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reginster, Jean Yves" sort="Reginster, Jean Yves" uniqKey="Reginster J" first="Jean-Yves" last="Reginster">Jean-Yves Reginster</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
<affiliation><nlm:affiliation>Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.</nlm:affiliation>
<wicri:noCountry code="subField">Kingdom of Saudi Arabia</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Rabenda, Veronique" sort="Rabenda, Veronique" uniqKey="Rabenda V" first="Véronique" last="Rabenda">Véronique Rabenda</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Geerinck, Anton" sort="Geerinck, Anton" uniqKey="Geerinck A" first="Anton" last="Geerinck">Anton Geerinck</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mkinsi, Ouafa" sort="Mkinsi, Ouafa" uniqKey="Mkinsi O" first="Ouafa" last="Mkinsi">Ouafa Mkinsi</name>
<affiliation wicri:level="1"><nlm:affiliation>Rheumatology Department, IBN ROCHD University Hospital, Casablanca, Morocco.</nlm:affiliation>
<country xml:lang="fr">Maroc</country>
<wicri:regionArea>Rheumatology Department, IBN ROCHD University Hospital, Casablanca</wicri:regionArea>
<wicri:noRegion>Casablanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Charles, Alexia" sort="Charles, Alexia" uniqKey="Charles A" first="Alexia" last="Charles">Alexia Charles</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rizzoli, Rene" sort="Rizzoli, Rene" uniqKey="Rizzoli R" first="Rene" last="Rizzoli">Rene Rizzoli</name>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva</wicri:regionArea>
<wicri:noRegion>Geneva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cooper, Cyrus" sort="Cooper, Cyrus" uniqKey="Cooper C" first="Cyrus" last="Cooper">Cyrus Cooper</name>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton</wicri:regionArea>
<wicri:noRegion>Southampton</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Avouac, Bernard" sort="Avouac, Bernard" uniqKey="Avouac B" first="Bernard" last="Avouac">Bernard Avouac</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bruyere, Olivier" sort="Bruyere, Olivier" uniqKey="Bruyere O" first="Olivier" last="Bruyère">Olivier Bruyère</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31073924</idno>
<idno type="pmid">31073924</idno>
<idno type="doi">10.1007/s40266-019-00662-z</idno>
<idno type="pmc">PMC6509099</idno>
<idno type="wicri:Area/Main/Corpus">000251</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000251</idno>
<idno type="wicri:Area/Main/Curation">000251</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000251</idno>
<idno type="wicri:Area/Main/Exploration">000251</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.</title>
<author><name sortKey="Honvo, Germain" sort="Honvo, Germain" uniqKey="Honvo G" first="Germain" last="Honvo">Germain Honvo</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. germain.honvo@uliege.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium. germain.honvo@uliege.be.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Reginster, Jean Yves" sort="Reginster, Jean Yves" uniqKey="Reginster J" first="Jean-Yves" last="Reginster">Jean-Yves Reginster</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
<affiliation><nlm:affiliation>Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.</nlm:affiliation>
<wicri:noCountry code="subField">Kingdom of Saudi Arabia</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Rabenda, Veronique" sort="Rabenda, Veronique" uniqKey="Rabenda V" first="Véronique" last="Rabenda">Véronique Rabenda</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Geerinck, Anton" sort="Geerinck, Anton" uniqKey="Geerinck A" first="Anton" last="Geerinck">Anton Geerinck</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mkinsi, Ouafa" sort="Mkinsi, Ouafa" uniqKey="Mkinsi O" first="Ouafa" last="Mkinsi">Ouafa Mkinsi</name>
<affiliation wicri:level="1"><nlm:affiliation>Rheumatology Department, IBN ROCHD University Hospital, Casablanca, Morocco.</nlm:affiliation>
<country xml:lang="fr">Maroc</country>
<wicri:regionArea>Rheumatology Department, IBN ROCHD University Hospital, Casablanca</wicri:regionArea>
<wicri:noRegion>Casablanca</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Charles, Alexia" sort="Charles, Alexia" uniqKey="Charles A" first="Alexia" last="Charles">Alexia Charles</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rizzoli, Rene" sort="Rizzoli, Rene" uniqKey="Rizzoli R" first="Rene" last="Rizzoli">Rene Rizzoli</name>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</nlm:affiliation>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva</wicri:regionArea>
<wicri:noRegion>Geneva</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cooper, Cyrus" sort="Cooper, Cyrus" uniqKey="Cooper C" first="Cyrus" last="Cooper">Cyrus Cooper</name>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton</wicri:regionArea>
<wicri:noRegion>Southampton</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Avouac, Bernard" sort="Avouac, Bernard" uniqKey="Avouac B" first="Bernard" last="Avouac">Bernard Avouac</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bruyere, Olivier" sort="Bruyere, Olivier" uniqKey="Bruyere O" first="Olivier" last="Bruyère">Olivier Bruyère</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège</wicri:regionArea>
<orgName type="university">Université de Liège</orgName>
<placeName><settlement type="city">Liège</settlement>
<region type="region" nuts="1">Région wallonne</region>
<region type="province" nuts="1">Province de Liège</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège</wicri:regionArea>
<wicri:noRegion>Liège</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Drugs & aging</title>
<idno type="eISSN">1179-1969</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anthraquinones (administration & dosage)</term>
<term>Anthraquinones (adverse effects)</term>
<term>Anthraquinones (therapeutic use)</term>
<term>Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)</term>
<term>Anti-Inflammatory Agents, Non-Steroidal (adverse effects)</term>
<term>Delayed-Action Preparations (MeSH)</term>
<term>Drug Combinations (MeSH)</term>
<term>Drug-Related Side Effects and Adverse Reactions (epidemiology)</term>
<term>Drug-Related Side Effects and Adverse Reactions (etiology)</term>
<term>Humans (MeSH)</term>
<term>Osteoarthritis (drug therapy)</term>
<term>Phytosterols (administration & dosage)</term>
<term>Phytosterols (adverse effects)</term>
<term>Phytosterols (therapeutic use)</term>
<term>Plant Extracts (administration & dosage)</term>
<term>Plant Extracts (adverse effects)</term>
<term>Plant Extracts (therapeutic use)</term>
<term>Randomized Controlled Trials as Topic (MeSH)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Vitamin E (administration & dosage)</term>
<term>Vitamin E (adverse effects)</term>
<term>Vitamin E (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Anthraquinones (administration et posologie)</term>
<term>Anthraquinones (effets indésirables)</term>
<term>Anthraquinones (usage thérapeutique)</term>
<term>Anti-inflammatoires non stéroïdiens (administration et posologie)</term>
<term>Anti-inflammatoires non stéroïdiens (effets indésirables)</term>
<term>Arthrose (traitement médicamenteux)</term>
<term>Association médicamenteuse (MeSH)</term>
<term>Effets secondaires indésirables des médicaments (épidémiologie)</term>
<term>Effets secondaires indésirables des médicaments (étiologie)</term>
<term>Essais contrôlés randomisés comme sujet (MeSH)</term>
<term>Extraits de plantes (administration et posologie)</term>
<term>Extraits de plantes (effets indésirables)</term>
<term>Extraits de plantes (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Phytostérols (administration et posologie)</term>
<term>Phytostérols (effets indésirables)</term>
<term>Phytostérols (usage thérapeutique)</term>
<term>Préparations à action retardée (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Vitamine E (administration et posologie)</term>
<term>Vitamine E (effets indésirables)</term>
<term>Vitamine E (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anthraquinones</term>
<term>Anti-Inflammatory Agents, Non-Steroidal</term>
<term>Phytosterols</term>
<term>Plant Extracts</term>
<term>Vitamin E</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anthraquinones</term>
<term>Anti-Inflammatory Agents, Non-Steroidal</term>
<term>Phytosterols</term>
<term>Plant Extracts</term>
<term>Vitamin E</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anthraquinones</term>
<term>Phytosterols</term>
<term>Plant Extracts</term>
<term>Vitamin E</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Delayed-Action Preparations</term>
<term>Drug Combinations</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anthraquinones</term>
<term>Anti-inflammatoires non stéroïdiens</term>
<term>Extraits de plantes</term>
<term>Phytostérols</term>
<term>Vitamine E</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Osteoarthritis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anthraquinones</term>
<term>Anti-inflammatoires non stéroïdiens</term>
<term>Extraits de plantes</term>
<term>Phytostérols</term>
<term>Vitamine E</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Arthrose</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anthraquinones</term>
<term>Extraits de plantes</term>
<term>Phytostérols</term>
<term>Vitamine E</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Association médicamenteuse</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Préparations à action retardée</term>
<term>Résultat thérapeutique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are an important drug class in the treatment armamentarium for osteoarthritis (OA).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>We aimed to re-assess the safety of various SYSADOAs in a comprehensive meta-analysis of randomized placebo-controlled trials, using, as much as possible, data from full safety reports.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We performed a systematic review and random-effects meta-analyses of randomized, double-blind, placebo-controlled trials that assessed adverse events (AEs) with various SYSADOAs in patients with OA. The databases MEDLINE, Cochrane Central Register of Controlled Trials (Ovid CENTRAL) and Scopus were searched. The primary outcomes were overall severe and serious AEs, as well as AEs involving the following Medical Dictionary for Regulatory Activities (MedDRA) system organ classes (SOCs): gastrointestinal, cardiac, vascular, nervous system, skin and subcutaneous tissue, musculoskeletal and connective tissue, renal and urinary system.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Database searches initially identified 3815 records. After exclusions according to the selection criteria, 25 studies on various SYSADOAs were included in the qualitative synthesis, and 13 studies with adequate data were included in the meta-analyses. Next, from the studies previously excluded according to the protocol, 37 with mainly oral nonsteroidal anti-inflammatory drugs (NSAIDs) permitted as concomitant medication were included in a parallel qualitative synthesis, from which 18 studies on various SYSADOAs were included in parallel meta-analyses. This post hoc parallel inclusion was conducted because of the high number of studies allowing concomitant anti-OA medications. Indeed, primarily excluding studies with concomitant anti-OA medications was crucial for a meta-analysis on safety. The decision for parallel inclusion was made for the purpose of comparative analyses. Glucosamine sulfate (GS), chondroitin sulfate (CS) and avocado soybean unsaponifiables (ASU; Piascledine</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>GS and CS can be considered safe treatments for patients with OA. All eligible studies on ASU included in our analysis used the proprietary product Piascledine</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31073924</PMID>
<DateCompleted><Year>2019</Year>
<Month>07</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1969</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>36</Volume>
<Issue>Suppl 1</Issue>
<PubDate><Year>2019</Year>
<Month>04</Month>
</PubDate>
</JournalIssue>
<Title>Drugs & aging</Title>
<ISOAbbreviation>Drugs Aging</ISOAbbreviation>
</Journal>
<ArticleTitle>Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.</ArticleTitle>
<Pagination><MedlinePgn>65-99</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s40266-019-00662-z</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are an important drug class in the treatment armamentarium for osteoarthritis (OA).</AbstractText>
<AbstractText Label="OBJECTIVE">We aimed to re-assess the safety of various SYSADOAs in a comprehensive meta-analysis of randomized placebo-controlled trials, using, as much as possible, data from full safety reports.</AbstractText>
<AbstractText Label="METHODS">We performed a systematic review and random-effects meta-analyses of randomized, double-blind, placebo-controlled trials that assessed adverse events (AEs) with various SYSADOAs in patients with OA. The databases MEDLINE, Cochrane Central Register of Controlled Trials (Ovid CENTRAL) and Scopus were searched. The primary outcomes were overall severe and serious AEs, as well as AEs involving the following Medical Dictionary for Regulatory Activities (MedDRA) system organ classes (SOCs): gastrointestinal, cardiac, vascular, nervous system, skin and subcutaneous tissue, musculoskeletal and connective tissue, renal and urinary system.</AbstractText>
<AbstractText Label="RESULTS">Database searches initially identified 3815 records. After exclusions according to the selection criteria, 25 studies on various SYSADOAs were included in the qualitative synthesis, and 13 studies with adequate data were included in the meta-analyses. Next, from the studies previously excluded according to the protocol, 37 with mainly oral nonsteroidal anti-inflammatory drugs (NSAIDs) permitted as concomitant medication were included in a parallel qualitative synthesis, from which 18 studies on various SYSADOAs were included in parallel meta-analyses. This post hoc parallel inclusion was conducted because of the high number of studies allowing concomitant anti-OA medications. Indeed, primarily excluding studies with concomitant anti-OA medications was crucial for a meta-analysis on safety. The decision for parallel inclusion was made for the purpose of comparative analyses. Glucosamine sulfate (GS), chondroitin sulfate (CS) and avocado soybean unsaponifiables (ASU; Piascledine<sup>®</sup>
) were not associated with increased odds for any type of AEs compared with placebo. Overall, with/without concomitant OA medication, diacerein was associated with significantly increased odds of total AEs (odds ratio [OR] 2.22; 95% confidence interval [CI] 1.58-3.13; I<sup>2</sup>
 = 52.8%), gastrointestinal disorders (OR 2.85; 95% CI 2.02-4.04; I<sup>2</sup>
 = 62.8%) and renal and urinary disorders (OR 3.42; 95% CI 2.36-4.96; I<sup>2</sup>
 = 17.0%) compared with placebo. In studies that allowed concomitant OA medications, diacerein was associated with significantly more dermatological disorders (OR 2.47; 95% CI 1.42-4.31; I<sup>2</sup>
 = 0%) and more dropouts due to AEs (OR 3.18; 95% CI 1.85-5.47; I<sup>2</sup>
 = 13.4%) than was placebo. No significant increase in serious or severe AEs was found with diacerein versus placebo.</AbstractText>
<AbstractText Label="CONCLUSIONS">GS and CS can be considered safe treatments for patients with OA. All eligible studies on ASU included in our analysis used the proprietary product Piascledine<sup>®</sup>
 and allowed other anti-OA medications; thus, the safety of ASU must be confirmed in future studies without concomitant anti-OA medications. Given the safety concerns with diacerein, its usefulness in patients with OA should be assessed, taking into account individual patient characteristics.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Honvo</LastName>
<ForeName>Germain</ForeName>
<Initials>G</Initials>
<Identifier Source="ORCID">0000-0002-6992-6712</Identifier>
<AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. germain.honvo@uliege.be.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium. germain.honvo@uliege.be.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Reginster</LastName>
<ForeName>Jean-Yves</ForeName>
<Initials>JY</Initials>
<Identifier Source="ORCID">0000-0001-6290-752X</Identifier>
<AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rabenda</LastName>
<ForeName>Véronique</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Geerinck</LastName>
<ForeName>Anton</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mkinsi</LastName>
<ForeName>Ouafa</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Rheumatology Department, IBN ROCHD University Hospital, Casablanca, Morocco.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Charles</LastName>
<ForeName>Alexia</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rizzoli</LastName>
<ForeName>Rene</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cooper</LastName>
<ForeName>Cyrus</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Avouac</LastName>
<ForeName>Bernard</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bruyère</LastName>
<ForeName>Olivier</ForeName>
<Initials>O</Initials>
<Identifier Source="ORCID">0000-0003-4269-9393</Identifier>
<AffiliationInfo><Affiliation>Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging, Liège, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>MC_U147585819</GrantID>
<Acronym>MRC_</Acronym>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>MC_UP_A620_1014</GrantID>
<Acronym>MRC_</Acronym>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>MC_UU_12011/1</GrantID>
<Acronym>MRC_</Acronym>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>G0400491</GrantID>
<Acronym>MRC_</Acronym>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>MC_U147585824</GrantID>
<Acronym>MRC_</Acronym>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>New Zealand</Country>
<MedlineTA>Drugs Aging</MedlineTA>
<NlmUniqueID>9102074</NlmUniqueID>
<ISSNLinking>1170-229X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000880">Anthraquinones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010840">Phytosterols</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C003884">piascledine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>1406-18-4</RegistryNumber>
<NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4HU6J11EL5</RegistryNumber>
<NameOfSubstance UI="C025292">diacetylrhein</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000880" MajorTopicYN="N">Anthraquinones</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010003" MajorTopicYN="N">Osteoarthritis</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010840" MajorTopicYN="N">Phytosterols</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>5</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>5</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>7</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31073924</ArticleId>
<ArticleId IdType="doi">10.1007/s40266-019-00662-z</ArticleId>
<ArticleId IdType="pii">10.1007/s40266-019-00662-z</ArticleId>
<ArticleId IdType="pmc">PMC6509099</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Stat Med. 1999 Feb 15;18(3):321-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10070677</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>West J Med. 2000 Feb;172(2):91-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10693368</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2000 Sep;8(5):343-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10966840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2000 Oct;43(10):2339-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11037895</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 2001 Jan;28(1):173-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11196521</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2001 Jan 27;357(9252):251-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11214126</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Therapie. 2001 Mar-Apr;56(2):190-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11471374</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 1994 Mar;2(1):51-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11548224</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Rheumatol. 2001;30(4):242-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11578021</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2001 Nov;44(11):2539-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11710710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2002 Feb;47(1):50-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11932878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2002 Mar;41(3):279-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11934964</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stat Med. 2002 Jun 15;21(11):1539-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Intern Med. 2002 Oct 14;162(18):2113-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12374520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Presse Med. 2002 Sep 14;31(29):1386-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12375395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2003 Sep 6;327(7414):557-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2003 Dec;62(12):1145-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14644851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Rhum Mal Osteoartic. 1992 Jul-Sep;59(7-8):466-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1485136</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2004 Apr;12(4):269-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15023378</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2004 Dec;63(12):1611-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15331394</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2004 Oct 15;51(5):738-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15478160</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2005 Mar;52(3):779-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15751094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15846645</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stat Med. 2006 Oct 30;25(20):3443-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16345038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2006 Feb 23;354(8):795-808</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16495392</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stat Med. 2007 Jan 15;26(1):53-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16596572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2007 May;66(5):639-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17204566</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2007 Feb;56(2):555-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17265490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Drug Investig. 2004;24(6):353-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17516722</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2007 Jul;56(7):2105-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17599727</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2007 Dec;56(12):4055-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18050202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nutr J. 2008 Jan 21;7:3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18208600</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nutr J. 2008 Feb 17;7:9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18279523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2008 Feb 19;148(4):268-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18283204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2008 Oct;16(10):1275-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18420430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2009 Feb;60(2):524-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19180484</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Food Sci Nutr. 2009;60 Suppl 2:99-113</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19212858</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Epidemiol. 2009 Oct;62(10):1006-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19631508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2010 Mar;18(3):289-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19857509</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S28-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20399895</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S32-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20399899</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Stat Med. 2010 Dec 20;29(29):3046-67</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20827667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2010 Sep 16;341:c4675</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20847017</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Presse Med. 2010 Oct;39(10):e211-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20937576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Evid Based Complement Alternat Med. 2011;2011:724291</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20981160</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Epidemiol. 2011 Apr;64(4):383-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21195583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2011 Apr;19(4):399-405</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21251991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2011 Jun;70(6):982-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21367761</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2011 Jun 18;377(9783):2115-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21684382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2011 Jul 22;343:d4002</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21784880</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 2011 Nov;63(11):3383-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21898340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2011 Nov;19(11):1270-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21907813</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Dec;112(6):760-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22001199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Agric Food Chem. 2012 Apr 25;60(16):4096-101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22486722</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22563589</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Rheumatol. 2012 Sep;31(9):1347-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22729470</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2013 Jan;21(1):22-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23059756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2012 Dec 15;380(9859):2163-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23245607</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2014 Feb;73(2):376-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23345601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Ther. 2013 Apr;35(4):431-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23474153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2015 May;74(5):851-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24395557</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 2014 Mar;22(3):363-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24462672</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2014 May;53(5):937-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24489012</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2014 Feb 10;(2):CD005117</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24515444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheumatol. 2014 Apr;66(4):930-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24616448</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Ther Res Clin Exp. 2009 Jun;70(3):185-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24683229</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2014 May 22;(5):CD002947</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24848732</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Sci Food Agric. 2015 Mar 15;95(4):702-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24852756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Phytother Res. 2014 Nov;28(11):1625-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24853120</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Care Res (Hoboken). 2014 Dec;66(12):1844-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24905534</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Arthritis Rheum. 2014 Dec;44(3):253-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24953861</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Orthop Sci. 2014 Nov;19(6):933-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25308211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rheumatology (Oxford). 2015 May;54(5):860-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25339639</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cartilage. 2015 Jan;6(1):30-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25621100</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2015 Jan 28;1:CD005614</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25629804</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Res Opin. 2015 May;31(5):1041-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25753599</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2015 Nov 18;5:16827</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26576862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nutr J. 2016 Jan 29;15:14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26822714</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs Aging. 2016 Feb;33(2):75-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26849131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheumatol. 2017 Jan;69(1):77-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27477804</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Inflammopharmacology. 2016 Dec;24(6):377-388</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27761693</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eye (Lond). 2017 Mar;31(3):389-394</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27768119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Diabetes Care. 2017 Oct;40(10):1356-1363</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28818994</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Rheum Dis. 2018 Feb;77(2):e11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28939627</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2017 Oct 19;12(10):e0186554</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29049415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Aging Clin Exp Res. 2018 Feb;30(2):111-117</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29177637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Aging Clin Exp Res. 2018 Apr;30(4):411-412</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29468617</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2018 Sep 5;834:266-273</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30031796</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Control Clin Trials. 1986 Sep;7(3):177-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Res Opin. 1980;7(2):110-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7002479</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Ther. 1980;3(4):260-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7023675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 1994 Apr;37(4):529-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8147930</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterol Clin Biol. 1995 Oct;19(10):851-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8566572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 1997 Sep 13;315(7109):629-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9310563</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arthritis Rheum. 1998 Jan;41(1):81-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9433873</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Rhum Engl Ed. 1997 Dec;64(12):825-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9476272</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gastroenterol Clin Biol. 1997;21(10):795-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9587523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 1998 May;6 Suppl A:25-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9743816</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 1998 May;6 Suppl A:31-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9743817</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Osteoarthritis Cartilage. 1998 May;6 Suppl A:39-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9743819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 1998 Nov;35(5):347-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9839088</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Prat. 1998 Nov 1;48(17 Suppl):S31-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9865113</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Belgique</li>
<li>Maroc</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
</country>
<region><li>Angleterre</li>
<li>Oxfordshire</li>
<li>Province de Liège</li>
<li>Région wallonne</li>
</region>
<settlement><li>Liège</li>
<li>Oxford</li>
</settlement>
<orgName><li>Université d'Oxford</li>
<li>Université de Liège</li>
</orgName>
</list>
<tree><country name="Belgique"><region name="Région wallonne"><name sortKey="Honvo, Germain" sort="Honvo, Germain" uniqKey="Honvo G" first="Germain" last="Honvo">Germain Honvo</name>
</region>
<name sortKey="Avouac, Bernard" sort="Avouac, Bernard" uniqKey="Avouac B" first="Bernard" last="Avouac">Bernard Avouac</name>
<name sortKey="Bruyere, Olivier" sort="Bruyere, Olivier" uniqKey="Bruyere O" first="Olivier" last="Bruyère">Olivier Bruyère</name>
<name sortKey="Bruyere, Olivier" sort="Bruyere, Olivier" uniqKey="Bruyere O" first="Olivier" last="Bruyère">Olivier Bruyère</name>
<name sortKey="Charles, Alexia" sort="Charles, Alexia" uniqKey="Charles A" first="Alexia" last="Charles">Alexia Charles</name>
<name sortKey="Charles, Alexia" sort="Charles, Alexia" uniqKey="Charles A" first="Alexia" last="Charles">Alexia Charles</name>
<name sortKey="Cooper, Cyrus" sort="Cooper, Cyrus" uniqKey="Cooper C" first="Cyrus" last="Cooper">Cyrus Cooper</name>
<name sortKey="Geerinck, Anton" sort="Geerinck, Anton" uniqKey="Geerinck A" first="Anton" last="Geerinck">Anton Geerinck</name>
<name sortKey="Geerinck, Anton" sort="Geerinck, Anton" uniqKey="Geerinck A" first="Anton" last="Geerinck">Anton Geerinck</name>
<name sortKey="Honvo, Germain" sort="Honvo, Germain" uniqKey="Honvo G" first="Germain" last="Honvo">Germain Honvo</name>
<name sortKey="Rabenda, Veronique" sort="Rabenda, Veronique" uniqKey="Rabenda V" first="Véronique" last="Rabenda">Véronique Rabenda</name>
<name sortKey="Rabenda, Veronique" sort="Rabenda, Veronique" uniqKey="Rabenda V" first="Véronique" last="Rabenda">Véronique Rabenda</name>
<name sortKey="Reginster, Jean Yves" sort="Reginster, Jean Yves" uniqKey="Reginster J" first="Jean-Yves" last="Reginster">Jean-Yves Reginster</name>
<name sortKey="Reginster, Jean Yves" sort="Reginster, Jean Yves" uniqKey="Reginster J" first="Jean-Yves" last="Reginster">Jean-Yves Reginster</name>
<name sortKey="Rizzoli, Rene" sort="Rizzoli, Rene" uniqKey="Rizzoli R" first="Rene" last="Rizzoli">Rene Rizzoli</name>
</country>
<country name="Maroc"><noRegion><name sortKey="Mkinsi, Ouafa" sort="Mkinsi, Ouafa" uniqKey="Mkinsi O" first="Ouafa" last="Mkinsi">Ouafa Mkinsi</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Rizzoli, Rene" sort="Rizzoli, Rene" uniqKey="Rizzoli R" first="Rene" last="Rizzoli">Rene Rizzoli</name>
</noRegion>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Cooper, Cyrus" sort="Cooper, Cyrus" uniqKey="Cooper C" first="Cyrus" last="Cooper">Cyrus Cooper</name>
</noRegion>
<name sortKey="Cooper, Cyrus" sort="Cooper, Cyrus" uniqKey="Cooper C" first="Cyrus" last="Cooper">Cyrus Cooper</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MaghrebDataLibMedV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000220 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000220 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MaghrebDataLibMedV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31073924
   |texte=   Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31073924" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MaghrebDataLibMedV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Jun 17 16:21:50 2021. Site generation: Thu Jun 17 21:51:18 2021

	Serveur sur les données et bibliothèques médicales au Maghreb
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur sur les données et bibliothèques médicales au Maghreb

Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.

Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki